CLU1 Inhibitors
Clusterin, commonly referred to by its gene symbol CLU1, is a highly conserved glycoprotein that plays a pivotal role in a multitude of physiological processes, including lipid transport, cell adhesion, tissue remodeling, and the regulation of cellular responses to stress. The protein is characterized by its ability to interact with a wide range of molecular partners, thereby influencing various signaling pathways and cellular mechanisms. CLU1's involvement in modulating cellular processes is critical for maintaining cellular homeostasis and responding to pathological states. Its expression is tightly regulated, and alterations in its levels are associated with several pathophysiological conditions, highlighting its significance in cellular functioning and disease progression.
The inhibition of CLU1, or the disruption of its function, can occur through several mechanisms, reflecting its multifaceted role in cellular physiology. One primary mechanism of inhibition is through the direct interaction with its protein structure, which can alter its conformation and subsequently its ability to bind to other molecules or its capacity for proper localization within the cell. This alteration can disrupt the normal function of CLU1, including its role in cell-cell adhesion, lipid transportation, and protection against cellular stress. Additionally, the regulation of CLU1 expression can be modulated at the transcriptional level, where specific inhibitors can downregulate its expression by interfering with the transcription factors or signaling pathways that control the CLU1 gene's activity. Such inhibition can lead to a decrease in CLU1 protein levels, affecting the cellular processes it regulates. Furthermore, post-translational modifications of CLU1, such as phosphorylation, glycosylation, or ubiquitination, can also be targets for inhibition, impacting its stability, localization, or interaction with other cellular components. These mechanisms of inhibition underscore the complexity of CLU1's function within the cell and the intricate balance required for its regulatory roles.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Competitively inhibits ATP binding in the tyrosine kinase domain of EGFR, preventing autophosphorylation and subsequent activation of downstream signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Binds to the ATP-binding site of the EGFR tyrosine kinase, which inhibits the EGFR tyrosine kinase and blocks signal transduction pathways implicated in the proliferation and survival of cancer cells. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Reversibly inhibits both EGFR and HER2 kinases, leading to inhibition of downstream signaling pathways and cell cycle arrest. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $112.00 $194.00 | 13 | |
Irreversibly binds to and inhibits EGFR, HER2, and HER4, leading to the inhibition of tumor growth and angiogenesis. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Selectively and irreversibly inhibits EGFR mutants, including T790M, a common resistance mutation, by targeting the ATP-binding site. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits the tyrosine kinase activity of EGFR, as well as VEGFR and RET, leading to reduced angiogenesis and tumor cell growth. | ||||||
Pelitinib | 257933-82-7 | sc-208155 | 5 mg | $430.00 | ||
Irreversibly binds to and inhibits the EGFR tyrosine kinase, resulting in antitumor activity and apoptosis. | ||||||
Canertinib | 267243-28-7 | sc-207397 | 10 mg | $260.00 | 3 | |
Irreversible pan-erbB receptor tyrosine kinase inhibitor, including EGFR, leading to inhibition of cellular proliferation and angiogenesis. | ||||||
Neratinib | 698387-09-6 | sc-364549 sc-364549A sc-364549B sc-364549C sc-364549D | 5 mg 25 mg 100 mg 500 mg 1 g | $90.00 $210.00 $375.00 $740.00 $1225.00 | 4 | |
Irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, EGFR and HER2. | ||||||